Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

April 24, 2028

Study Completion Date

April 24, 2029

Conditions
DLL3-expressing TumorsAdvanced Tumors
Interventions
DRUG

Tarlatamab treatment

"* 1 mg step dose on cycle 1 day 1 (C1D1)~* 10 mg target dose on cycle 1 day 8 (C1D8), and cycle 1 day 15 (C1D15) in a 28-day cycle.~* 10 mg Q2W subsequently (i.e., C2 + D1/D15 dosing) in a 28-day cycle"

Trial Locations (5)

90095

RECRUITING

University of California at Los Angeles, Los Angeles

92093

NOT_YET_RECRUITING

UC San Diego Moores Cancer Center, San Diego

92612

NOT_YET_RECRUITING

UCI Health Chao Family Comprehensive Cancer Center, Irvine

94143

NOT_YET_RECRUITING

University of California at San Francisco, San Francisco

95817

NOT_YET_RECRUITING

UC Davis Comprehensive Cancer Center, Davis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER